Nausea and Vomiting
Also known as: Emesis
Methodology & AI Transparency ⓘ
Nausea and Vomiting Key Takeaways
Translated by Sarah Jenkins (AI RN Plain-English Translator) at a 7th-grade reading level
- 1 What it does: What are nausea and vomiting? Nausea is when you feel sick to your stomach, as if you are going to throw up.
- 2 Real-world patient consensus: Clinical coding for Nausea and Vomiting uses ICD-10 R11.10 across GERD & Stomach specialty care.
- 3 Typical cash cost range: Workup highlights for Nausea and Vomiting (R11.10): mucosal protective therapy [Nausea and Vomiting R11.10].
- 4 Top reported side effects / signs: Key GERD & Stomach biomarkers for Nausea and Vomiting (R11.10): Serum Vitamin B12 in Nausea and Vomiting (R11.10: & Magnesium (chronic) & H. pylori Stool in Nausea and Vomiting (R11.10: Antigen or Urea) (Negative (R11.10)).
Ask our AI Specialists anything about Nausea and Vomiting
What Is Nausea and Vomiting?
What are nausea and vomiting? Nausea is when you feel sick to your stomach, as if you are going to throw up. Vomiting is when you throw up. What causes nausea and vomiting? Nausea and vomiting can be symptoms of many different conditions, including: Morning sickness during pregnancy Gastroenteritis (infection of your intestines) and other infections Migraines Motion sickness Food poisoning Medicines, including those for cancer chemotherapy GERD (reflux) and ulcers Intestinal obstruction When do I need to see a health care provider for nausea and vomiting? Nausea and vomiting are common. They are usually not serious.
Pathophysiology, Underlying Causes & Clinical Presentation
Biological expression of Nausea and Vomiting (R11.10, GERD & Stomach) reflects visceral hypersensitivity [Nausea and Vomiting R11.10]. Cross-referenced with NIH MeSH (Vomiting, Nausea), longitudinal control is benchmarked via Serum Vitamin B12 in Nausea and Vomiting (R11.10: & Magnesium (chronic).
Common Symptoms & Clinical Signs
- • Morning sickness during pregnancy
- • Gastroenteritis (infection of your intestines) and other infections
- • Presentation of Nausea and Vomiting (R11.10): nausea, belching, or in Nausea and Vomiting (R11.10: discomfort relieved or)
- • Secondary Nausea and Vomiting clinical sign: post-meal retrosternal heartburn in Nausea and Vomiting (R11.10: or sour acid)
Primary Federal Reference: NIH / National Library of Medicine MedlinePlus Entry ↗
Nausea and Vomiting Diagnostic Classification & Lab Markers
| Metric | Verified Benchmark | Source |
|---|---|---|
| ICD-10-CM Diagnostic Code | R11.10 | WHO / CMS ICD-10-CM Clinical Classification |
| Clinical Specialty Hub | Acid Reflux, GERD & Upper GI Health | NIH MedlinePlus Health Topics |
| Diagnostic / Lab Marker: Serum Vitamin B12 in Nausea and Vomiting (R11.10: & Magnesium (chronic) | B12 > 450 pg/mL; Mg >= 2.0 mg/dL (R11.10) | Clinical Reference Target Range |
| Diagnostic / Lab Marker: H. pylori Stool in Nausea and Vomiting (R11.10: Antigen or Urea) | Negative (R11.10) | Clinical Reference Target Range |
| Diagnostic / Lab Marker: Hemoglobin & Serum in Nausea and Vomiting (R11.10: Ferritin) | Ferritin > 50 ng/mL (no occult loss) (R11.10) | Clinical Reference Target Range |
FDA-Monographed Medications & Public Cash Price Reference for Nausea and Vomiting
| Medication | Pharmacologic Class | Patient Worth-It | CMS NADAC / Unit | Typical Lowest Cash |
|---|---|---|---|---|
| Sancuso (Granisetron) Sancuso • RxCUI 825005 | Serotonin-3 Receptor Antagonist | 79% | $655.3031 | $ 640.00 /mo |
| Wal-Dram 2 Quick-Dissolving (Meclizine Hydrochloride) Wal-Dram 2 Quick-Dissolving • RxCUI 1663815 | Antiemetic | 93% | $0.0306 | $ 10.70 /mo |
| Sustol (Granisetron) Sustol • RxCUI 310599-B47426101 | Serotonin-3 Receptor Antagonist | 74% | $1.2117 | $ 95.74 /mo |
| Doxylamine Succinate and Pyridoxine Hydrochloride Diclegis, Bonjesta • RxCUI 1375948 | Antihistamine | 92% | $1.0916 | $ 52.71 /mo |
| Amisulpride Barhemsys • RxCUI 2284232 | Dopamine-2 Receptor Antagonist | 93% | $1.0900 | $ 52.65 /mo |
| Palonosetron Posfrea • RxCUI 1728050 | Serotonin-3 Receptor Antagonist | 84% | $1.6100 | $ 73.71 /mo |
| Ondansetron Zofran ODT • RxCUI 104894 | Serotonin-3 Receptor Antagonist | 85% | $0.1759 | $ 6.29 /mo |
| Droperidol Droperidol Generic • RxCUI 282485 | Dopamine-2 Receptor Antagonist | 93% | $2.7100 | $ 118.26 /mo |
| Netupitant and Palonosetron Akynzeo • RxCUI 1552343 | Substance P/Neurokinin-1 Receptor Antagonist | 81% | $2.5000 | $ 109.75 /mo |
| Dimenhydrinate Motion Sickness, Motion Sickness Relief • RxCUI 309914 | Histamine-1 Receptor Antagonist | 91% | $0.0478 | $ 10.44 /mo |
| Granisetron Sancuso, Sustol • RxCUI 825003 | Serotonin-3 Receptor Antagonist | 92% | $655.3031 | $ 25.87 /mo |
Peer-Reviewed Human Clinical Trials & Meta-Analyses (Nausea and Vomiting)
| Study & Plain-English Finding | Sample (N) | Rigor | Primary Source |
|---|---|---|---|
| New Insights on Olanzapine With or Without Fosaprepitant for Preventing Chemotherapy Induced: What a 690-Participant Study Found This trial did not provide sufficient evidence to support that deletion of the NK-1 receptor antagonist was as good as keeping it, as a part of a 4-drug antiemetic regimen for highly emetogenic chemotherapy. The oncologist • 2023-08-03 • Phase III Randomized Trial | N = 690 | 93/100 | PMID 37284847 ↗ |
| Can This Approach Help? Inside the Latest Research on Phase III randomized compared against a dummy pill (placebo) trial on repurposing Adding olanzapine 5 mg with standard antiemetics significantly reduced RINV during abdominal-pelvic radiation therapy. Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology • 2026-08-15 • Phase III Randomized Trial | N = 153 | 88/100 | PMID 42119640 ↗ |
| Can This Approach Help? Inside the Latest Research on Olanzapine combined with standard antiemetics for the prevention of nausea and Conclusion This trial provides the first high-level evidence supporting the olanzapine-based four-drug combination to prevent CINV in GCT patients undergoing 5-day cisplatin-based chemotherapy. European journal of cancer (Oxford, England : 1990) • 2025-06-03 • Phase III Randomized Trial | N = 77 | 88/100 | PMID 40311506 ↗ |
| New Insights on Pooled Analysis of Studies Evaluating Fosnetupitant and Risk Factors for: What a 980-Participant Study Found This analysis revealed that fosnetupitant could have long-acting antiemetic potency (> 120 h) and indicated the importance of antiemetic therapy at 0-120 h for CINV up to 168 h after chemotherapy. Advances in therapy • 2023-11-15 • Phase III Randomized Trial | N = 980 | 87/100 | PMID 37715851 ↗ |
| Can This Approach Help? Inside the Latest Research on Dexamethasone-sparing regimens with NEPA (netupitant/palonosetron) for the Among the 228 patients in the parent study, 107 were > 65 years. Journal of geriatric oncology • 2023-07-15 • Phase III Randomized Trial | Multi-cohort | 82/100 | PMID 37290207 ↗ |
Nausea and Vomiting Patient Community & “People Like Me” Threads
Filter Nausea and Vomiting community threads and patient logs by age, biological sex, dosage, and treatment duration.